You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金首次覆蓋藥明合聯(02268.HK)予「跑贏行業」評級 目標價40元
阿思達克 01-11 14:22
中金發表評級報告,預計藥明合聯(02268.HK)綜合項目將由去年6月的110個增至2025年超過160個,同時項目向臨床後期流動,在2023年至2025年收入複合年均增長率為60%,同時公司有望於2024至2025年起,兩個BLA項目商業化批次生產。中金預計,隨著無錫新產能投產,公司毛利率將由2022年的26.4%增至2025年的35%以上。 中金預計,公司在2023年至2025年經調整每股盈測分別為0.31元人民幣、0.53元人民幣、0.88元人民幣,複合年均增長率為70%。另外,中金看好偶聯藥物外包行業成長性及公司的全球競爭力。 中金表示,首次覆蓋藥明合聯,並給予其目標價為40元,其評級為「跑贏行業」。(ca/cy) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account